Sanofi Japan To Start Generic Drug Sales, Aiming At ¥30 Billion In Five Years
This article was originally published in PharmAsia News
Executive Summary
Sanofi Japan will make a full-scale entry into the Japanese generic market by beginning the independent sale of generic forms of Diovan and zoledronic acid from June.